Comparison of Pharmacokinetics and Safety of Two Formulations of Letrozole (2.5 mg) in Healthy Male Volunteers

건강한 성인 남성에서 두 가지 제형의 레트로졸정의 약동학 특성 및 안전성 비교

  • Noh, Yook-Hwan (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) ;
  • Bae, Kyun-Seop (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) ;
  • Cho, Sang-Heon (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) ;
  • Choe, Sangmin (Clinical Trials Center, Pusan National University Hospital) ;
  • Ghim, Jong-Lyul (Department of Clinical Pharmacology, Busan Paik Hospital) ;
  • Jung, Jin Ah (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center) ;
  • Kim, Un-Jib (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) ;
  • Jin, Seok-Joon (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center) ;
  • Park, Hyun-Jung (Pharmacokinetic and Pharmacogenetic Laboratory, Clinical Trial Center, Asan Medical Center) ;
  • Kim, Jung-Chul (Pharmacokinetic and Pharmacogenetic Laboratory, Clinical Trial Center, Asan Medical Center) ;
  • Lim, Hyeong-Seok (Department of Clinical Pharmacology and Therapeutics, Asan Medical Center)
  • 노육환 (서울아산병원 임상약리학과) ;
  • 배균섭 (서울아산병원 임상약리학과) ;
  • 조상헌 (서울대학교 의과대학 약리학교실 및 서울대학교 병원 임상약리학과) ;
  • 최상민 (부산대학교병원 임상시험센터) ;
  • 김종률 (인제대학교 부산백병원 임상약리학과) ;
  • 정진아 (삼성서울병원 임상약리학과) ;
  • 김운집 (서울아산병원 임상약리학과) ;
  • 진석준 (서울아산병원 임상약리학과) ;
  • 박현정 (서울아산병원 임상시험센터 약동약력연구실) ;
  • 김정철 (서울아산병원 임상시험센터 약동약력연구실) ;
  • 임형석 (서울아산병원 임상약리학과)
  • Received : 2012.07.11
  • Accepted : 2012.09.25
  • Published : 2012.12.31

Abstract

Background: Letrozole is an oral non-steroidal inhibitor of the aromatase enzyme, which has proven to be a useful drug against breast cancer. Methods: This single-dose, randomized $2{\times}2$ crossover study was conducted in healthy male volunteers. Participants of each sequence group (each 13 volunteers for sequence group) received, in randomized sequence, a single oral 2.5-mg dose of generic letrozole (test) or branded letrozole (reference). Each treatment period was separated by a 5-week washout period. Blood samples were collected for up to 312 hours after drug administration, and drug concentrations were determined using validated LC/MS-MS. Pharmacokinetic properties were obtained using noncompartmental analysis. Drug tolerability was assessed throughout the study, using measurements of vital signs, physical examination, clinical chemistry testing, EKG, and interviews. Results: A total of 26 subjects completed the study. The geometric mean ratios (90% CI) of $C_{max}$ and $AUC_{last}$ were 0.92 (0.85 - 0.99) and 1.01 (0.97 - 1.04), respectively. No serious AEs were reported, and there were no clinically significant differences between test and reference groups. Conclusion: The findings from this study suggest bioequivalence between two formulations of letrozole in healthy male volunteers. The safety profile of two formulations had similar characteristics.

배경: 레트로졸은 유방암 치료에 사용되는 경구용 비스테로이드성 aromatase 억제제이다. 방법: 이 연구는 건강한 성인 남성을 대상으로 무작위 배정, 단회 투여, 공개설계로서 두 치료군, 두 순서, 두 시기의 교차 시험법으로 진행되었다. 각 순서군에 13명씩 무작위 배정되어, 한군은 1기에 페마라$^{(R)}$정(대조약)을, 2기에 유한 레트로졸정(시험약)을, 다른 한군은 반대 순서로 두 시기 사이에 약 5주의 휴약기를 가지고 각각 2.5 mg정 1정씩 투여 받았다. 약동학 분석을 위한 혈액 검체는 공복 상태에서 투약 후 312 시간까지 얻어졌다. 레트로졸의 혈장 내 농도는 liquid chromatography-tandem mass spectrometry를 이용하여 측정하였다. 안전성 평가는 활력징후, 문진 및 신체검사, 심전도, 진단검사실 검사와 이상반응 모니터링을 통하여 이루어졌다. 결과: 총 26명의 피험자가 연구를 완료하였고, 약동학 분석에 26명의 자료가 모두 사용되었다. $C_{max}$$AUC_{last}$ 파라미터에 대한 시험약과 대조약의 기하평균비는 각각 0.92 (90 % 신뢰구간: 0.85 - 0.99)와 1.01 (90 % 신뢰구간: 0.97 - 1.04)였다. 보고된 중대한 이상반응은 없었으며, 임상적으로 유의한 변화도 관찰되지 않았다. 결론: 건강한 자원자에서 페마라$^{(R)}$정과 유한 레트로졸정의 약동학 특성과 안전성은 유사하였다.

Keywords

References

  1. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 2004;9(2):126-136. https://doi.org/10.1634/theoncologist.9-2-126
  2. Dellapasqua S, Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol, 2010;6(2):251-259. https://doi.org/10.1517/17425250903540246
  3. KFDA. Korea good clinical practice (KGCP) guidelines. http://clinicaltrials.kfda.go.kr/guide/ laws/board_list.jsp?category_seq=12 [Online] (last visited on 07 July 2012).
  4. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policie s/b3/ [Online] (last visited on 07 July 2012).
  5. Marfil F, Pineau V, Sioufi A, Godbillon SJ. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J Chromatogr B Biomed Appl, 1996;683(2):251-258. https://doi.org/10.1016/0378-4347(96)00118-1
  6. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J Pharm Biomed Anal, 2007;44(1):250-253. https://doi.org/10.1016/j.jpba.2007.01.026
  7. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed, Wolters, Kluwer/Lippincott, Williams & Wilkins, 2011.
  8. KFDA. Bioequivalence guideline in Korea. Published by Korea Food and Drug Administration; http://www.kfda.go.kr/index.kfda?mid=226&pag eNo=1&seq=139&cmd=v [Online] (last visited on July 07 2012).
  9. Lonning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol, 2003;30(4 Suppl 14):23-32. https://doi.org/10.1016/S0093-7754(03)70022-0
  10. Noh YH, Ko YJ, Cho SH, Ghim JL, Choe S, Jung JA, Kim UJ, Jin SJ, Park HJ, Song GS, Lim HS. Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, singledose, 2-period, 2-sequence, crossover study. Clin Ther, 2012;34(2):305-313. https://doi.org/10.1016/j.clinthera.2012.01.008